Identification

Name
Fosinopril
Accession Number
DB00492  (APRD00526)
Type
Small Molecule
Groups
Approved
Description

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
  • (2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
  • (2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • Fosinopril
Product Ingredients
IngredientUNIICASInChI Key
Fosinopril SodiumNW2RTH6T2N88889-14-9TVTJZMHAIQQZTL-HREVRLCXSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-fosinoprilTablet20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-fosinoprilTablet10 mgOralAvanstra Inc2011-11-282014-08-21Canada
FosinoprilTablet10 mgOralSanis Health Inc2017-04-11Not applicableCanada
FosinoprilTablet20 mgOralSanis Health Inc2017-04-11Not applicableCanada
Fosinopril TabletsTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril TabletsTablet20 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril-10Tablet10 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Fosinopril-20Tablet20 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Jamp-fosinoprilTablet10 mgOralJamp Pharma Corporation2010-05-17Not applicableCanada
Jamp-fosinoprilTablet20 mgOralJamp Pharma Corporation2010-05-17Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fosinoprilTablet20 mgOralApotex Corporation2005-04-27Not applicableCanada
Apo-fosinoprilTablet10 mgOralApotex Corporation2005-04-27Not applicableCanada
FOSINOPRIL NaTablet40 mg/1OralApotex Corporation2005-05-182017-02-24Us60505 2512 02 nlmimage10 ee3f775b
FOSINOPRIL NaTablet10 mg/1OralApotex Corporation2005-05-182017-02-24Us
FOSINOPRIL NaTablet20 mg/1OralApotex Corporation2005-05-182017-02-24Us
Fosinopril sodiumTablet20 mg/1OralAphena Pharma Solutions Tennessee, Inc.2005-06-21Not applicableUs
Fosinopril SodiumTablet10 mg/1OralCamber Pharmaceuticals2007-09-17Not applicableUs
Fosinopril SodiumTablet40 mg/1OralGolden State Medical Supply2011-12-27Not applicableUs
Fosinopril SodiumTablet40 1/1OralCipla Limited2016-06-162017-10-02Us
Fosinopril SodiumTablet20 mg/1OralTeva2003-12-01Not applicableUs
International/Other Brands
Acecor (SPA (Czech Republic)) / Monopril (Bristol-Myers Squibb) / Staril (BMS (United Kingdom))
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralEon Labs, Inc.2005-09-28Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAurobindo Pharma2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2005-11-15Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralGlenmark Pharmaceuticals Inc.,Usa2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRanbaxy Inc.2004-12-20Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralEon Labs, Inc.2005-09-28Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAurobindo Pharma2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril Sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralCitron Pharma LLC2009-07-09Not applicableUs
Categories
UNII
R43D2573WO
CAS number
98048-97-6
Weight
Average: 563.6625
Monoisotopic: 563.301189343
Chemical Formula
C30H46NO7P
InChI Key
BIDNLKIUORFRQP-FKDWWROVSA-N
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
IUPAC Name
(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid
SMILES
CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[[email protected]@H](C[[email protected]]1C(O)=O)C1CCCCC1)C(C)C

Pharmacology

Indication

For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications
Pharmacodynamics

Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.

Volume of distribution
Not Available
Protein binding

Fosinoprilat is ≥95% protein bound

Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

Route of elimination

After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.

Half life

12 hours

Clearance
  • 26 - 39 mL/min [healthy]
Toxicity

Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fosinopril Action PathwayDrug action
Fosinopril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fosinopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Fosinopril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Acemetacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Fosinopril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fosinopril.Approved, Investigational
AlgeldrateThe serum concentration of Fosinopril can be decreased when it is combined with Algeldrate.Experimental
AliskirenAliskiren may increase the hyperkalemic activities of Fosinopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.Approved
AlmagateThe serum concentration of Fosinopril can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Fosinopril can be decreased when it is combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Fosinopril.Approved
AloglutamolThe serum concentration of Fosinopril can be decreased when it is combined with Aloglutamol.Experimental
AloxiprinAloxiprin may decrease the antihypertensive activities of Fosinopril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fosinopril.Approved, Illicit, Investigational
AlprenololFosinopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumThe serum concentration of Fosinopril can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Fosinopril can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Fosinopril can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.Approved
AmbrisentanFosinopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Fosinopril.Experimental
AmifostineFosinopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Fosinopril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Fosinopril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Fosinopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fosinopril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fosinopril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Fosinopril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Fosinopril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Fosinopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fosinopril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Fosinopril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Fosinopril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.Withdrawn
AzathioprineFosinopril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Fosinopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Fosinopril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Fosinopril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Fosinopril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Fosinopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Fosinopril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benoxaprofen.Withdrawn
BepridilFosinopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Fosinopril.Approved
BethanidineBethanidine may increase the hypotensive activities of Fosinopril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Fosinopril.Experimental
BimatoprostFosinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Fosinopril can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Fosinopril can be decreased when it is combined with Bismuth subnitrate.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Fosinopril can be decreased when it is combined with Boceprevir.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fosinopril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Fosinopril.Approved, Investigational
BQ-123Fosinopril may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Fosinopril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Fosinopril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosinopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosinopril.Approved, Investigational
BupranololFosinopril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Fosinopril.Approved
CadralazineCadralazine may increase the hypotensive activities of Fosinopril.Experimental
CafedrineFosinopril may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateThe serum concentration of Fosinopril can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Fosinopril can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Fosinopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.Approved
CandoxatrilFosinopril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Captopril.Approved
CarbamazepineThe metabolism of Fosinopril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Fosinopril.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fosinopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Fosinopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Celecoxib.Approved, Investigational
CeliprololFosinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Fosinopril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Fosinopril.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosinopril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Fosinopril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Choline magnesium trisalicylate.Approved
CicletanineFosinopril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fosinopril.Approved
CiprofloxacinFosinopril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Fosinopril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fosinopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Fosinopril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonixin.Approved
CloranololFosinopril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosinopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fosinopril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Fosinopril.Approved
CryptenamineFosinopril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Fosinopril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.Approved
CyclopenthiazideFosinopril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.Approved, Investigational, Vet Approved
CyclothiazideFosinopril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Fosinopril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Fosinopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Fosinopril.Approved
DelaprilFosinopril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Fosinopril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Fosinopril.Investigational
DeserpidineFosinopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosinopril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Fosinopril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Fosinopril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Fosinopril.Approved
diethylnorspermineFosinopril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosinopril.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Fosinopril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fosinopril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Fosinopril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fosinopril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.Approved
DorzolamideFosinopril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fosinopril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Fosinopril.Approved
DrospirenoneFosinopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Droxicam.Approved
DuloxetineFosinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Fosinopril.Approved
E-6201The risk or severity of adverse effects can be increased when Fosinopril is combined with E-6201.Investigational
EfonidipineFosinopril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Enalapril.Approved, Vet Approved
EnalaprilatFosinopril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Fosinopril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Fosinopril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Fosinopril.Approved
EpanololFosinopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Fosinopril.Approved
EpoprostenolFosinopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Fosinopril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Fosinopril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Fosinopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Fosinopril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Fosinopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Fosinopril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosinopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Fosinopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.Approved
exisulindThe risk or severity of adverse effects can be increased when Fosinopril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenbufen.Approved
FenoldopamFosinopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Feprazone.Experimental
Ferulic acidFosinopril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fosinopril.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.Experimental
FurazolidoneFurazolidone may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Fosinopril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Fosinopril.Experimental
GuanabenzFosinopril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Fosinopril.Approved
GuanazodineFosinopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Fosinopril.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Guanfacine.Approved, Investigational
GuanoclorFosinopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFosinopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFosinopril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Fosinopril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Fosinopril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Fosinopril.Approved, Investigational
HexamethoniumFosinopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Fosinopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Fosinopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Fosinopril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFosinopril may increase the hypotensive activities of Hydroflumethiazide.Approved
HydrotalciteThe serum concentration of Fosinopril can be decreased when it is combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Fosinopril.Approved
IloprostIloprost may increase the hypotensive activities of Fosinopril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Fosinopril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indapamide.Approved
IndenololFosinopril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Fosinopril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Fosinopril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Fosinopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Fosinopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fosinopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fosinopril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Fosinopril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Fosinopril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Labetalol.Approved
LacidipineFosinopril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostFosinopril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Leflunomide.Approved, Investigational
LercanidipineFosinopril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fosinopril.Approved
LevodopaFosinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Fosinopril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril.Approved
LinsidomineFosinopril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fosinopril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Fosinopril.Experimental
LofexidineFosinopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Fosinopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lumiracoxib.Approved, Investigational
MacitentanFosinopril may increase the hypotensive activities of Macitentan.Approved
MagaldrateThe serum concentration of Fosinopril can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium HydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineFosinopril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Fosinopril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Fosinopril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Fosinopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Fosinopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fosinopril.Approved
MethoserpidineFosinopril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fosinopril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Fosinopril.Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Fosinopril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fosinopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fosinopril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Fosinopril.Approved, Investigational
MetyrosineFosinopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilFosinopril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Fosinopril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Fosinopril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Fosinopril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Fosinopril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Fosinopril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Fosinopril.Approved
MuzolimineFosinopril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fosinopril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Fosinopril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naftifine.Approved
NaftopidilFosinopril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Fosinopril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Fosinopril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Fosinopril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.Approved
NiguldipineFosinopril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFosinopril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Fosinopril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Fosinopril.Approved
NitrendipineFosinopril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Fosinopril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Fosinopril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Fosinopril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.Approved
ObinutuzumabFosinopril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Fosinopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.Approved
OmapatrilatFosinopril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Fosinopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxaprozin.Approved
OxprenololFosinopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Fosinopril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Fosinopril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
PentoliniumFosinopril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fosinopril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Fosinopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fosinopril.Approved
PhenoxybenzamineFosinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhentolamineFosinopril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Fosinopril.Approved
PinacidilPinacidil may increase the hypotensive activities of Fosinopril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril.Approved
PiretanidePiretanide may increase the hypotensive activities of Fosinopril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Fosinopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Fosinopril.Withdrawn
PolythiazideFosinopril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Fosinopril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pranoprofen.Experimental
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Fosinopril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fosinopril.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.Approved
PTC299The risk or severity of adverse effects can be increased when Fosinopril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Fosinopril.Approved
QuinineQuinine may increase the hypotensive activities of Fosinopril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Fosinopril.Approved
RasagilineRasagiline may increase the hypotensive activities of Fosinopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Fosinopril.Approved
RescinnamineFosinopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fosinopril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Fosinopril.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Fosinopril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Fosinopril.Approved
RisperidoneFosinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFosinopril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosinopril.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Fosinopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Fosinopril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Fosinopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Fosinopril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fosinopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Fosinopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
SelexipagFosinopril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Fosinopril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Fosinopril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosinopril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Fosinopril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fosinopril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fosinopril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.Approved, Investigational
SitaxentanFosinopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Fosinopril.Approved
Sodium phosphateFosinopril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.Approved
SpiraprilFosinopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.Approved
SRT501The risk or severity of adverse effects can be increased when Fosinopril is combined with SRT501.Investigational
St. John's WortThe metabolism of Fosinopril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Fosinopril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Fosinopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fosinopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
TalinololFosinopril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Fosinopril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.Approved, Investigational
TemocaprilFosinopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Teriflunomide.Approved
TerlipressinFosinopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineFosinopril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fosinopril.Approved, Investigational, Withdrawn
TheodrenalineFosinopril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Fosinopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosinopril.Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Fosinopril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tiaprofenic acid.Approved
TiboloneFosinopril may increase the hypotensive activities of Tibolone.Approved
TicrynafenFosinopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Fosinopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Fosinopril.Approved
TipranavirThe serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Fosinopril.Approved
TolazolineFosinopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosinopril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolmetin.Approved
TolonidineFosinopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Fosinopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Fosinopril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Fosinopril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Fosinopril.Approved
TravoprostTravoprost may increase the hypotensive activities of Fosinopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Fosinopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Fosinopril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Fosinopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Fosinopril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tribenoside.Experimental
TrichlormethiazideFosinopril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Fosinopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Fosinopril.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fosinopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
UnoprostoneFosinopril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Fosinopril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Fosinopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Fosinopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Fosinopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Fosinopril.Approved, Investigational
VincamineFosinopril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineFosinopril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideFosinopril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFosinopril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Fosinopril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Fosinopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilFosinopril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zomepirac.Withdrawn
Food Interactions
  • Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
  • Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of fosinopril.
  • Take without regard to meals.

References

Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.

US20050010054
General References
  1. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791]
  2. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]
External Links
Human Metabolome Database
HMDB14635
KEGG Drug
D00622
KEGG Compound
C07016
PubChem Compound
55891
PubChem Substance
46506495
ChemSpider
50469
ChEBI
5163
ChEMBL
CHEMBL3306578
Therapeutic Targets Database
DAP000582
PharmGKB
PA449710
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fosinopril
ATC Codes
C09AA09 — FosinoprilC09BA09 — Fosinopril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (206 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionCardiovascular Disease (CVD) / Heart Diseases / Hypertensive1
2CompletedTreatmentDiabetic Nephropathies1
3CompletedPreventionCardiovascular Disease (CVD) / Microalbuminuria / Renal Diseases1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentHypertensive1
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Chronic Kidney Insufficiency / Proteinuria1

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Invagen pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral10 1/1
TabletOral20 1/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral40 1/1
TabletOral
TabletOral10 mg
TabletOral20 mg
Prices
Unit descriptionCostUnit
Monopril HCT 10-12.5 mg tablet1.71USD tablet
Monopril 10 mg tablet1.68USD tablet
Monopril 40 mg tablet1.67USD tablet
Monopril 20 mg tablet1.62USD tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet1.61USD tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet1.61USD tablet
Fosinopril sodium 20 mg tablet1.25USD tablet
Fosinopril sodium 40 mg tablet1.25USD tablet
Fosinopril sodium 10 mg tablet1.21USD tablet
Monopril 20 mg Tablet1.1USD tablet
Monopril 10 mg Tablet0.91USD tablet
Apo-Fosinopril 20 mg Tablet0.61USD tablet
Fosinopril 20 mg Tablet0.61USD tablet
Jamp-Fosinopril 20 mg Tablet0.61USD tablet
Mylan-Fosinopril 20 mg Tablet0.61USD tablet
Novo-Fosinopril 20 mg Tablet0.61USD tablet
Ran-Fosinopril 20 mg Tablet0.61USD tablet
Apo-Fosinopril 10 mg Tablet0.51USD tablet
Fosinopril 10 mg Tablet0.51USD tablet
Jamp-Fosinopril 10 mg Tablet0.51USD tablet
Mylan-Fosinopril 10 mg Tablet0.51USD tablet
Novo-Fosinopril 10 mg Tablet0.51USD tablet
Ran-Fosinopril 10 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006344No1993-01-102010-01-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-153 °CNot Available
water solubilityInsolubleNot Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00101 mg/mLALOGPS
logP4.71ALOGPS
logP5.49ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.87ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.21 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity149.12 m3·mol-1ChemAxon
Polarizability61.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9532
Blood Brain Barrier-0.667
Caco-2 permeable-0.6561
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.6774
Renal organic cation transporterNon-inhibitor0.812
CYP450 2C9 substrateNon-substrate0.7028
CYP450 2D6 substrateNon-substrate0.8128
CYP450 3A4 substrateSubstrate0.6729
CYP450 1A2 substrateNon-inhibitor0.8913
CYP450 2C9 inhibitorNon-inhibitor0.7438
CYP450 2D6 inhibitorNon-inhibitor0.9004
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorNon-inhibitor0.7303
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6376
Ames testNon AMES toxic0.7141
CarcinogenicityNon-carcinogens0.8025
BiodegradationNot ready biodegradable0.8102
Rat acute toxicity2.8211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9534
hERG inhibition (predictor II)Non-inhibitor0.5918
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0000900000-f61a6a8a62cc0c92102b
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0000900000-ed280398ec57e4a02dce
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090300000-4e1c300644a39a64aefe
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090000000-85f8c80f83290feea35c
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0090000000-e28a43e299ff58e3a6bc
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0010900000-a142ed389f6652d197f1
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1090000000-833fa43a37b31e08737c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1090000000-cda46913f10b57e39204
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-2290000000-8627963d14d5d091e338
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0229-7890000000-a5186e8ef5fa038d0a91
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03k9-9720000000-ff0242177e3d4ef6c38a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000f-0000900000-a2e65cd39ca7266f3a02
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0000900000-0eee13fe1a605e98c985
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00ku-0105900000-1253dd1cea86dcfde7f6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udl-0908200000-59ff4955c6e6b2d36435
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0901000000-e2b0d1bb8bfd4d6f7595
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0000900000-f625a00c8eb75cbf317d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6x-0409200000-5a18b8096c457898aa5f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-28e69824d7a0442561b6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-aa95f5f65aec2f92a48a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2900000000-48b3327e8691a43ae029
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-6900000000-de8ad752f1c8f05aded2

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Phosphinic acid esters / Carboxylic acid esters / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Proline or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives / Dicarboxylic acid or derivatives / Monocyclic benzene moiety / Benzenoid
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
L-proline derivative, phosphinic ester (CHEBI:5163)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  4. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:34